On April 14, the Finnish Pharmaceuticals Pricing Board (HILA) rejected Novo’s application for reimbursement and a reasonable wholesale price for Wegovy. Novo states that it applied for limited basic reimbursement for the treatment of obesity (Finnish Medical Journal, April 24, 2026).
3 Likes